{"count": 2, "results": [{"_id": "2924074", "pmid": 2924074, "title": "Atenolol, but not mexiletine, protects against stimulus-induced ventricular tachycardia in a chronic canine model.", "journal": "Br J Pharmacol", "authors": ["Uprichard AC", "Harron DW"], "date": "1989-01-01T00:00:00Z", "doi": "10.1111/j.1476-5381.1989.tb11803.x", "meta_date_publication": "1989 Jan", "meta_volume": "96", "meta_issue": "1", "meta_pages": "220-6", "score": 50059.55, "text_hl": "Effective (ERP) and functional (FRP) refractory periods did not change after @CHEMICAL_Mexiletine @CHEMICAL_MESH:D008801 @@@mexiletine@@@, but ERP was prolonged (P less than 0.05) after @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. 4. The results indicate that @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ but not @CHEMICAL_Mexiletine @CHEMICAL_MESH:D008801 @@@mexiletine@@@ is effective in preventing @<m>DISEASE_Reinfection</m> @DISEASE_MESH:D000084063 @@@re-@@@entrant @DISEASE_Arrhythmias_Cardiac @DISEASE_MESH:D001145 @@@arrhythmias@@@ in this conscious @SPECIES_9615 @@@canine@@@ model. ", "citations": {"NLM": "Uprichard AC, Harron DW. Atenolol, but not mexiletine, protects against stimulus-induced ventricular tachycardia in a chronic canine model. Br J Pharmacol. 1989 Jan;96(1):220-6. PMID: 2924074", "BibTeX": "@article{2924074, title={Atenolol, but not mexiletine, protects against stimulus-induced ventricular tachycardia in a chronic canine model.}, author={Uprichard AC and Harron DW}, journal={Br J Pharmacol}, volume={96}, number={1}, pages={220-6}}"}}, {"_id": "1372217", "pmid": 1372217, "title": "Wolff-Parkinson-White syndrome. Identification and management.", "journal": "Drugs", "authors": ["Gaita F", "Giustetto C", "Riccardi R", "Brusca A"], "date": "1992-02-01T00:00:00Z", "doi": "10.2165/00003495-199243020-00005", "meta_date_publication": "1992 Feb", "meta_volume": "43", "meta_issue": "2", "meta_pages": "185-200", "score": 50038.99, "text_hl": "Vaughan-Williams class IC anti-arrhythmic drugs (@CHEMICAL_Propafenone @CHEMICAL_MESH:D011405 @@@propafenone@@@, @CHEMICAL_Flecainide @CHEMICAL_MESH:D005424 @@@flecainide@@@) are the first choice for drugs in @SPECIES_9606 @@@patients@@@ with rapid anterograde conduction through the accessory pathway due to their high efficacy and low incidence of adverse effects, while beta-blockers (@<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, @CHEMICAL_Nadolol @CHEMICAL_MESH:D009248 @@@nadolol@@@) are indicated for @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Reinfection</m> @DISEASE_MESH:D000084063 @@@re-@@@entrant @DISEASE_Tachycardia @DISEASE_MESH:D013610 @@@tachycardias@@@ and low conduction capacity through the bypass tract. ", "citations": {"NLM": "Gaita F, Giustetto C, Riccardi R, Brusca A. Wolff-Parkinson-White syndrome. Identification and management. Drugs. 1992 Feb;43(2):185-200. PMID: 1372217", "BibTeX": "@article{1372217, title={Wolff-Parkinson-White syndrome. Identification and management.}, author={Gaita F and Giustetto C and Riccardi R and Brusca A}, journal={Drugs}, volume={43}, number={2}, pages={185-200}}"}}]}